A two-year oncogenicity study in rats (intramuscular administration of Faslodex) showed increased incidence of ovarian benign granulosa cell tumours in female rats at the high dose, 10 mg/ rat/ 15 days and an increased incidence of testicular Leydig cell tumours in males.